Tabrecta can be prescribed at hospitals

The first MET anticancer drug

Passed the Pharmaceutical Affairs Committee including Samsung Medical Center.

According to related industries, Tabrecta of Novartis Korea passed the D.C.

 

of medical institutions such as the National Cancer Center, Pusan National University Hospital, Samsung Seoul Hospital, and Sinchon Severance Hospital.

 

Tabrecta, which is currently undergoing the insurance benefit registration process, was approved in Korea in November last year.

 

MET mutations are rare types that account for about 3% to 4% of metastatic non-small cell lung cancer, and as there have been no treatments, interest in these new drugs is increasing.

 

Tabrecta targets c-Met and was first approved in the United States as a non-small cell Lung Cancer treatment in May 2020.

 

The drug was validated by a phase 2 GEOMETRY mono-1 study of 97 patients with METex14.

 

As a result of the study, the overall response rate was 68% in patients who had never been treated and 41% in patients who had previously been treated.

 

Among patients who took Tabrecta, patients who had not previously been treated (DoR was 12.6 months and those who had been treated were 9.7 months.

 

Tabrecta is also stepping up research for future combination therapy.

 

In particular, it is expected to solve the resistance problem of EGFR TKI in lung cancer.

 

Tabrecta is conducting clinical trials in combination with AstraZeneca's third-generation EGFR TKI Tagrisso.

 

Specifically, combination therapy of Tabrecta and Tagrisso is compared with platinum-based chemotherapy for EGFR mutated non-small cell lung cancer patients with T790M negative and amplified MET genes during treatment with first and second generations EGFR TKI or Tagrisso.

 

Han Ji-yeon, a professor of hematology and oncology at the National Cancer Center, said, "The prognosis of patients with MET amplification is also very poor.

 

At a time when it is very important for MET inhibitors to enter the market quickly, it is significant that drugs such as Tabrecta, which proved a clear effect only on MET Exxon 14 deficit mutations, were approved."